AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24118844 — intervention group
Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 161
Study 24118844 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires (Pelvic Floor Impact Questionnaire, Pelvic Floor Distress Inventory, Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire)
Number of subjects: 161
Study 24119174 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPHAISTOS unloading orthosis for 56 days
Number of subjects: 11
Study 24119247 — intervention group
Group type: EXPERIMENTAL
Intervention: T. cruzi I
Number of subjects: 30000
Study 24119247 — intervention group
Group type: COMPARATOR
Intervention: Non-I
Number of subjects: 30000
Study 24119319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5mg
Number of subjects: 1913
Study 24119319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg
Number of subjects: 1913
Study 24119319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1913
Study 24119533 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational community resource use (nutrition and physical activity classes)
Number of subjects: 207
Study 24119533 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 207
Study 24119533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer depressive symptoms
Number of subjects: 207
Study 24119589 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 15545
Study 24119590 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart added to existing basal insulin (n=519)
Number of subjects: 66726
Study 24119590 — intervention group
Group type: EXPERIMENTAL
Intervention: Switched from biphasic insulin (n=947)
Number of subjects: 66726
Study 24119590 — intervention group
Group type: EXPERIMENTAL
Intervention: Switched from NPH plus human meal-time insulins (n=586)
Number of subjects: 66726
Study 24119590 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-naïve begun with basal plus insulin aspart (n=1594)
Number of subjects: 66726
Study 24119776 — intervention group
Group type: EXPERIMENTAL
Intervention: Accommodative insole
Number of subjects: 21
Study 24120120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 fortified bread (125 μg daily) for 1 year
Number of subjects: 23
Study 24120253 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once daily for 52 weeks
Number of subjects: 3091
Study 24120253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3091
Study 24120271 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-item Chinese version of Stroke-Specific Quality of Life Scale (SSQOL-a)
Number of subjects: 186
Study 24120271 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-item Chinese version of SSQOL-a
Number of subjects: 186
Study 24120338 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostatic powder (21 g applied during endoscopy)
Number of subjects: 9
Study 24120380 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg, 150 mg, 225 mg, and 300 mg given orally once daily for 27 days
Number of subjects: 19
Study 24120380 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 19
Study 24120629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralow risk group (pretest probability < 2.5%)
Number of subjects: 840
Study 24120629 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 840
Study 24121121 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CMT) using doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) plus involved-field radiation therapy (IFRT)
Number of subjects: 588
Study 24121121 — intervention group
Group type: COMPARATOR
Intervention: ABVD alone
Number of subjects: 588
Study 24121121 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CMT)
Number of subjects: 588
Study 24121121 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD in HD10 eligible patients achieving complete response (CR) or unconfirmed complete response (CRu) after two cycles
Number of subjects: 588
Study 24121121 — intervention group
Group type: COMPARATOR
Intervention: ABVD in HD.6 eligible patients achieving complete response (CR) or unconfirmed complete response (CRu) after two cycles
Number of subjects: 588
Study 24121121 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD in HD10 eligible patients not achieving CR/CRu after two cycles
Number of subjects: 588
Study 24121121 — intervention group
Group type: COMPARATOR
Intervention: ABVD in HD.6 eligible patients not achieving CR/CRu after two cycles
Number of subjects: 588
Study 24121151 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 24122237 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment during childhood
Number of subjects: 1204
Study 24122387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg daily and dexamethasone 8 mg once weekly (part I)
Number of subjects: 27
Study 24122387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg daily and dexamethasone 8 mg once weekly plus rituximab 375 mg/m2 (part II)
Number of subjects: 27
Study 24122387 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (lenalidomide, low-dose dexamethasone, and rituximab)
Number of subjects: 27
Study 24122452 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilator stress CMR
Number of subjects: 151
Study 24122452 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 151
Study 24122508 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology
Number of subjects: 46887
Study 24122508 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV testing
Number of subjects: 46887
Study 24122716 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 249
Study 24122913 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Auto Profile (Atherotech Inc.)
Number of subjects: 1340614
Study 24122913 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Large Database of Lipids 1.0
Number of subjects: 1340614
Study 24122961 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT for >3 months
Number of subjects: 56440
Study 24122961 — intervention group
Group type: COMPARATOR
Intervention: DAPT for 3 months
Number of subjects: 56440
Study 24122961 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT for >6 months
Number of subjects: 56440
Study 24123804 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet counts < 60 × 10(9) /L on postoperative day 5 (POD5)
Number of subjects: 257
Study 24123804 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet counts < 60 × 10(9) /L on POD5
Number of subjects: 257
Study 24124377 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified relaxation (MR) technique
Number of subjects: 432
Study 24124377 — intervention group
Group type: COMPARATOR
Intervention: Control group (health education)
Number of subjects: 432
Study 24124874 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24125537 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterodigital arterialised nerve pedicle flap
Number of subjects: 12
Study 24125537 — intervention group
Group type: COMPARATOR
Intervention: Cross-finger flap and secondary nerve grafting
Number of subjects: 12
Study 24126237 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) with risedronate
Number of subjects: 63
Study 24126237 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) without bisphosphonate therapy
Number of subjects: 63
Study 24126237 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure to suppress bone turnover markers while receiving ADT
Number of subjects: 63
Study 24126537 — intervention group
Group type: EXPERIMENTAL
Intervention: Huntington disease
Number of subjects: 334
Study 24127057 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniscus surgery for traumatic tears
Number of subjects: 0
Study 24127057 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniscus surgery for non-traumatic tears
Number of subjects: 0
Study 24127452 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidilizumab (anti-PD-1 monoclonal antibody), administered as three doses beginning 1 to 3 months after AHSCT.
Number of subjects: 66
Study 24127479 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 444
Study 24127479 — intervention group
Group type: COMPARATOR
Intervention: Control (no palivizumab)
Number of subjects: 444
Study 24128118 — intervention group
Group type: EXPERIMENTAL
Intervention: REBA MTB-Rifa® assay
Number of subjects: 720
Study 24128118 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug-susceptibility testing (DST)
Number of subjects: 720
Study 24128336 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin A status (serum retinol <1·05 μmol/l)
Number of subjects: 391
Study 24128336 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin A status
Number of subjects: 391
Study 24128336 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle vitamin A tertile (1·056-1·298 μmol/l)
Number of subjects: 391
Study 24128336 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentration of serum retinol
Number of subjects: 391
Study 24128336 — intervention group
Group type: COMPARATOR
Intervention: Fe deficiency
Number of subjects: 391
Study 24128439 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D (1100IU/day) for at least 12 months
Number of subjects: 446
Study 24128439 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation study with 145 extended independent white postmenopausal women
Number of subjects: 446
Study 24128669 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-626529 (an attachment inhibitor administered as the prodrug BMS-663068)
Number of subjects: 0
Study 24128669 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-626529
Number of subjects: 0
Study 24128715 — intervention group
Group type: EXPERIMENTAL
Intervention: ROS1 rearrangement screening in resected NSCLC patients
Number of subjects: 515
Study 24128715 — intervention group
Group type: EXPERIMENTAL
Intervention: ROS1 rearrangement screening in advanced pulmonary adenocarcinoma patients
Number of subjects: 515
Study 24129642 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 111
Study 24129642 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 111
Study 24130359 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese
Number of subjects: 270
Study 24130359 — intervention group
Group type: COMPARATOR
Intervention: Caucasians
Number of subjects: 270
Study 24130359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 270
Study 24130359 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition measures (BMI and adipose tissue distribution)
Number of subjects: 270
Study 24130359 — intervention group
Group type: COMPARATOR
Intervention: Differences in β-cell response
Number of subjects: 270
Study 24130489 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) for 24 weeks
Number of subjects: 16
Study 24130673 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based multimodal intervention for suicide prevention
Number of subjects: 631133
Study 24130673 — intervention group
Group type: COMPARATOR
Intervention: Prevention-as-usual control group
Number of subjects: 631133
Study 24130889 — intervention group
Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 50
Study 24131282 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-12 240 mg twice daily
Number of subjects: 0
Study 24131282 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-12 240 mg three times daily
Number of subjects: 0
Study 24131282 — intervention group
Group type: COMPARATOR
Intervention: BG-12
Number of subjects: 0
Study 24131779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinaciclib (0.33 mg/m2 to 14 mg/m2, 2-hour intravenous infusion once weekly for 3 weeks)
Number of subjects: 48
Study 24131779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinaciclib at RP2D (12 mg/m2)
Number of subjects: 48
Study 24131779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinaciclib (various doses)
Number of subjects: 48
Study 24131779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinaciclib (all doses)
Number of subjects: 48
Study 24132072 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom-Him intervention (experimental arm)
Number of subjects: 60
Study 24132072 — intervention group
Group type: COMPARATOR
Intervention: Control arm (viewing a list of websites containing HIV/AIDS related information)
Number of subjects: 60
Study 24132357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative computed tomography (CT) imaging at Center A
Number of subjects: 36
Study 24132357 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoroscopic imaging at Center B
Number of subjects: 36
Study 24132613 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg daily
Number of subjects: 0
Study 24132613 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg daily
Number of subjects: 0
Study 24133188 — intervention group
Group type: EXPERIMENTAL
Intervention: PfRH5-specific IgG
Number of subjects: 357
Study 24133188 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated PfRH5-specific IgG
Number of subjects: 357
Study 24134154 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide (subcutaneously for 24 weeks)
Number of subjects: 0
Study 24134154 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneously for 24 weeks)
Number of subjects: 0
Study 24134221 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1-specific antibody responses to transmembrane glycoprotein (TM) and reverse transcriptase (RT)
Number of subjects: 0
Study 24134221 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1-specific antibody responses to surface glycoprotein (SU), capsid (CA), matrix (MA), and integrase (IN)
Number of subjects: 0
Study 24134221 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1-specific antibody responses to capsid (CA), matrix (MA), and integrase (IN)
Number of subjects: 0
Study 24134221 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1-specific antibody responses to capsid (CA) and integrase (IN)
Number of subjects: 0
Study 24135755 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive optics scanning laser ophthalmoscopy (AOSLO) imaging
Number of subjects: 7
Study 24135755 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical measures
Number of subjects: 7
Study 24136099 — intervention group
Group type: EXPERIMENTAL
Intervention: Control Preference Scale at baseline (n=405) and 1 year later (n=314)
Number of subjects: 405
Study 24136099 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making Questionnaire (SDM-Q-9) in a subgroup of patients (n=108)
Number of subjects: 405
Study 24136113 — intervention group
Group type: COMPARATOR
Intervention: HIV-monoinfected
Number of subjects: 569
Study 24136113 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HCV coinfection
Number of subjects: 569
Study 24136113 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV in HIV-infected participants
Number of subjects: 569
Study 24136335 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24136369 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 598
Study 24136934 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-CP-18
Number of subjects: 7
Study 24138429 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional polynomial model
Number of subjects: 0
Study 24138429 — intervention group
Group type: COMPARATOR
Intervention: Power-law model
Number of subjects: 0
Study 24138784 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training during 24 weeks
Number of subjects: 94
Study 24138784 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 94
Study 24138831 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 15
Study 24138944 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC) 20mg/m² intravenously daily for 5 days followed by rapamycin at doses of 2 mg, 4 mg, and 6 mg/day from day 6 to day 25
Number of subjects: 12
Study 24139066 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT
Number of subjects: 44
Study 24139066 — intervention group
Group type: EXPERIMENTAL
Intervention: IPDT
Number of subjects: 44
Study 24139613 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy consisting of 2 cycles of cisplatin and etoposide combined with 45 Gy of thoracic radiotherapy
Number of subjects: 22
Study 24139613 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 22
Study 24140121 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoCell (35, 70, 140, or 210 × 10(6) cell/kg)
Number of subjects: 13
Study 24140121 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoCell
Number of subjects: 13
Study 24140121 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoCell (higher doses)
Number of subjects: 13
Study 24140416 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Brugada pattern on ECG in DM1 patients
Number of subjects: 914
Study 24140416 — intervention group
Group type: EXPERIMENTAL
Intervention: SCN5A sequencing
Number of subjects: 914
Study 24140416 — intervention group
Group type: COMPARATOR
Intervention: Ventricular myocardial specimen analysis
Number of subjects: 914
Study 24141377 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated hepatic perfusion (IHP)
Number of subjects: 34
Study 24141377 — intervention group
Group type: COMPARATOR
Intervention: Control group (longest surviving patients in Sweden with uveal melanoma liver metastases not treated with IHP)
Number of subjects: 34
Study 24141969 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent technology intervention (internet-delivered programme, portable pedal machine, pedometer for 12 weeks)
Number of subjects: 49
Study 24141969 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (maintained behaviours for 12 weeks)
Number of subjects: 49
Study 24142996 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat/azacitidine/gemtuzumab ozogamicin
Number of subjects: 52
Study 24143213 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype GA/AA of SNP rs2306283 of the gene SLCO1B1
Number of subjects: 137
Study 24143213 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype GG of SNP rs1051266 of the gene SLC19A1
Number of subjects: 137
Study 24143213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both genotypes (GA/AA of rs2306283 and GG of rs1051266)
Number of subjects: 137
Study 24144215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 15 mg/kg
Number of subjects: 60
Study 24144215 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 15 mg/kg
Number of subjects: 60
Study 24144215 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 60
Study 24144505 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (specifics not provided)
Number of subjects: 47
Study 24144643 — intervention group
Group type: EXPERIMENTAL
Intervention: GEP70 risk score >-0.26
Number of subjects: 331
Study 24144643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of elevated serum free light chain, M-spike, and GEP70 risk score
Number of subjects: 331
Study 24144643 — intervention group
Group type: COMPARATOR
Intervention: Absence of elevated serum free light chain, M-spike, and GEP70 risk score
Number of subjects: 331
Study 24144643 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of multiple (>1) focal lesions by MRI
Number of subjects: 331
Study 24145340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated hypofractionated radiotherapy (RT) with total doses ranging from 57 to 85.5 Gy in 25 daily fractions over 5 weeks using intensity-modulated radiotherapy.
Number of subjects: 79
Study 24145340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated hypofractionated radiotherapy (RT)
Number of subjects: 79
Study 24145345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with vaccine
Number of subjects: 90
Study 24145345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab at 3 mg/kg with or without peptide vaccine
Number of subjects: 90
Study 24145345 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 90
Study 24145345 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 90
Study 24145457 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain Relaxation Index (SRI)
Number of subjects: 1544
Study 24145657 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 0
Study 24145802 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated patients (urinary specific gravity 1.020 or higher)
Number of subjects: 45
Study 24145802 — intervention group
Group type: COMPARATOR
Intervention: Euhydrated patients (urinary specific gravity less than 1.020)
Number of subjects: 45
Study 24145880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir (ATVr) 300/100 mg every 24 hours
Number of subjects: 14
Study 24145880 — intervention group
Group type: COMPARATOR
Intervention: Unboosted atazanavir (200 mg every 12 hours)
Number of subjects: 14
Study 24145879 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir as a film-coated tablet 400 mg twice daily (6 to <19 years, and ≥ 25 kg)
Number of subjects: 96
Study 24145879 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir as a chewable tablet 6 mg/kg (maximum dose 300 mg) twice daily (2 to <12 years)
Number of subjects: 96
Study 24145879 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (both formulations)
Number of subjects: 96
Study 24146089 — intervention group
Group type: EXPERIMENTAL
Intervention: CTGF plus NT-proBNP
Number of subjects: 212
Study 24146089 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP alone
Number of subjects: 212
Study 24146089 — intervention group
Group type: EXPERIMENTAL
Intervention: CTGF levels
Number of subjects: 212
Study 24146089 — intervention group
Group type: EXPERIMENTAL
Intervention: CTGF levels in HFREF patients
Number of subjects: 212
Study 24146089 — intervention group
Group type: EXPERIMENTAL
Intervention: CTGF levels in HFPEF patients
Number of subjects: 212